Literature DB >> 21272100

Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Kavita Prasad1, Elizabeth Tarasewicz, Pamela A Ohman Strickland, Michael O'Neill, Stephen N Mitchell, Kalpana Merchant, Samnang Tep, Kathryn Hilton, Akash Datwani, Manuel Buttini, Sarah Mueller-Steiner, Eric K Richfield.   

Abstract

A consensus about the functions of human wild-type or mutated α-synuclein (αSYN) is lacking. Both forms of αSYN are implicated in Parkinson's disease, whereas the wild-type form is implicated in substance abuse. Interactions with other cellular proteins and organelles may meditate its functions. We developed a series of congenic mouse lines containing various allele doses or combinations of the human wild-type αSYN (hwαSYN) or a doubly mutated (A30P*A53T) αSYN (hm(2) αSYN) in a C57Bl/6J line spontaneously deleted in mouse αSYN (C57BL/6JOla). Both transgenes had a functional role in the nigrostriatal system, demonstrated by significant elevations in striatal catecholamines, metabolites and the enzyme tyrosine hydroxylase compared with null-mice without a transgene. Consequences occurred when the transgenes were expressed at a fraction of the endogenous level. Hemizygous congenic mice did not exhibit any change in the number or size of dopaminergic neurons in the ventral midbrain at 9 months of age. Human αSYN was predominantly located in neuronal cell bodies, neurites, synapses, and in intraneuronal/intraneuritic aggregates. The hm(2) αSYN transgene resulted in more aggregates and dystrophic neurites than did the hw5 transgene. The hwαSYN transgene resulted in higher expression of two striatal proteins, synaptogamin 7 and UCHL1, compared with the levels of the hm(2) αSYN transgene. These observations suggest that mutations in αSYN may impair specific functional domains, leaving others intact. These lines may be useful for exploring interactions between hαSYN and environmental or genetic risk factors in dopamine-related disorders using a mouse model.
© 2011 University of Medicine and Dentistry New Jersey. European Journal of Neuroscience © 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272100      PMCID: PMC3072281          DOI: 10.1111/j.1460-9568.2010.07558.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  80 in total

1.  Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum.

Authors:  Yujing Qin; Qinjie Ouyang; John Pablo; Deborah C Mash
Journal:  Neuroreport       Date:  2005-09-08       Impact factor: 1.837

2.  Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody.

Authors:  S Yu; X Li; G Liu; J Han; C Zhang; Y Li; S Xu; C Liu; Y Gao; H Yang; K Uéda; P Chan
Journal:  Neuroscience       Date:  2007-02-01       Impact factor: 3.590

3.  Linkage disequilibrium and association analysis of alpha-synuclein and alcohol and drug dependence in two American Indian populations.

Authors:  Jordi Clarimon; Rebecca R Gray; Lindsey N Williams; Mary-Anne Enoch; Robert W Robin; Bernard Albaugh; Andrew Singleton; David Goldman; Connie J Mulligan
Journal:  Alcohol Clin Exp Res       Date:  2007-04       Impact factor: 3.455

4.  Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence.

Authors:  D Bönsch; T Lederer; U Reulbach; T Hothorn; J Kornhuber; S Bleich
Journal:  Hum Mol Genet       Date:  2005-02-24       Impact factor: 6.150

Review 5.  Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

Authors:  O M El-Agnaf; G B Irvine
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

Review 6.  Synucleinopathies: clinical and pathological implications.

Authors:  J E Galvin; V M Lee; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-02

7.  Human substantia nigra neurons encode unexpected financial rewards.

Authors:  Kareem A Zaghloul; Justin A Blanco; Christoph T Weidemann; Kathryn McGill; Jurg L Jaggi; Gordon H Baltuch; Michael J Kahana
Journal:  Science       Date:  2009-03-13       Impact factor: 47.728

8.  Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats.

Authors:  Frederic Boyer; Jean-Luc Dreyer
Journal:  Eur J Neurosci       Date:  2007-11       Impact factor: 3.386

9.  Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus.

Authors:  Philip E Chen; Christian G Specht; Richard G M Morris; Ralf Schoepfer
Journal:  Eur J Neurosci       Date:  2002-07       Impact factor: 3.386

10.  Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

Authors:  Abdelmojib Al-Wandi; Natalia Ninkina; Steven Millership; Sally J M Williamson; Paul A Jones; Vladimir L Buchman
Journal:  Neurobiol Aging       Date:  2008-12-20       Impact factor: 4.673

View more
  9 in total

1.  In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy.

Authors:  Lidia Reznichenko; Qun Cheng; Krystal Nizar; Sergey L Gratiy; Payam A Saisan; Edward M Rockenstein; Tanya González; Christina Patrick; Brian Spencer; Paula Desplats; Anders M Dale; Anna Devor; Eliezer Masliah
Journal:  J Neurosci       Date:  2012-07-18       Impact factor: 6.167

2.  A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration.

Authors:  Linan Chen; Zhiguo Xie; Susie Turkson; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2015-01-21       Impact factor: 6.167

Review 3.  Parkinson's disease mouse models in translational research.

Authors:  Paul M A Antony; Nico J Diederich; Rudi Balling
Journal:  Mamm Genome       Date:  2011-05-11       Impact factor: 2.957

4.  Quantitative proteomics in A30P*A53T α-synuclein transgenic mice reveals upregulation of Sel1l.

Authors:  Jianguo Yan; Pei Zhang; Fengjuan Jiao; Qingzhi Wang; Feng He; Qian Zhang; Zheng Zhang; Zexi Lv; Xiang Peng; Hongwei Cai; Bo Tian
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

Review 5.  Historical Perspective: Models of Parkinson's Disease.

Authors:  Shyh Jenn Chia; Eng-King Tan; Yin-Xia Chao
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 5.923

Review 6.  Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease.

Authors:  Takeya Kitta; Mifuka Ouchi; Hiroki Chiba; Madoka Higuchi; Mio Togo; Yui Abe-Takahashi; Naohisa Kusakabe; Nobuo Shinohara
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

Review 7.  Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective.

Authors:  Rajashree Banerjee; Arushi Rai; Shreyas M Iyer; Sonia Narwal; Meghana Tare
Journal:  Animal Model Exp Med       Date:  2022-01-27

8.  A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.

Authors:  Marco A S Baptista; Kuldip D Dave; Niketa P Sheth; Shehan N De Silva; Kirsten M Carlson; Yasmin N Aziz; Brian K Fiske; Todd B Sherer; Mark A Frasier
Journal:  Dis Model Mech       Date:  2013-09-12       Impact factor: 5.758

9.  Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease.

Authors:  Falk Schlaudraff; Jan Gründemann; Michael Fauler; Elena Dragicevic; John Hardy; Birgit Liss
Journal:  Neurobiol Aging       Date:  2014-03-22       Impact factor: 4.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.